Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-
positive bacteria that was first approved for clinical use in 2004 in the United States. Since …

The treatment of multidrug-resistant enterococcal infections continues to be a challenge for
clinicians. Glycopeptide and β-lactam resistance is now a common feature of the majority of …

Background Daptomycin is a lipopeptide with bactericidal activity that acts on the cell
membrane of enterococci and is often used off-label to treat patients infected with …

Vancomycin-resistant enterococci (VRE) are the second leading cause of hospital-acquired
infections (HAIs) attributed to a drug-resistant bacterium in the United States, and resistance …

Treatment of multidrug-resistant enterococci has become a challenging clinical problem in
hospitals around the world due to the lack of reliable therapeutic options. Daptomycin (DAP) …

Enterococcus faecalis is a human intestinal pathobiont with intrinsic and acquired resistance
to many antibiotics, including vancomycin. Nature provides a diverse and virtually untapped …

Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice.
Their increased prevalence and their ability to transfer vancomycin resistance to other …

Over the past two decades infections due to antibiotic-resistant bacteria have escalated
world-wide, affecting patient morbidity, mortality, and health care costs. Among these …

Background The lipopeptide antibiotic, daptomycin (DAP) interacts with the bacterial cell
membrane (CM). Development of DAP resistance during therapy in a clinical strain of …

Daptomycin (DAP) is a lipopeptide antibiotic frequently used as a “last-resort” antibiotic
against vancomycin-resistant Enterococcus faecium (VRE). However, an important limitation …